Our Work
Latham & Watkins Advises Ascendis Pharma A/S in Its Royalty Funding Agreement With Royalty Pharma
September 6, 2023
A California-based team advises the biopharma company in one of the largest royalty transactions of 2023.
Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) announced that Ascendis has entered into a US$150 million capped synthetic royalty funding agreement with Royalty Pharma based on US net SKYTROFA revenue.
Latham & Watkins LLP represents Ascendis Pharma A/S in the transaction. The royalty funding agreement was led by partners Jekkie Kim and Haim Zaltzman, with associate Billy Wu. The corporate team was led by partners Mark Roeder and John Williams, with associates Tess Bloom and Tyler Israel. Advice was also provided on finance matters by partner Elizabeth Oh; and on tax matters by partner Eric Cho, with associate Sam Yang.